First Solar: The Cheapest Semiconductor Stock Nobody Is Watching — Value Opportunity or Value Trap?

First Solar: The Cheapest Semiconductor Stock Nobody Is Watching — Value Opportunity or Value Trap?

Almost nothing in semiconductor land is cheap right now. First Solar might be the exception — and that is worth paying attention to, even if you have never thought of a solar panel manufacturer as a chip stock.


First Solar trades at 12.7x forward earnings and 12.7x forward free cash flow. It carries over $2.4 billion in cash with almost no debt. It just reported record Q1 2026 revenue of just over $1 billion, up 24% year over year, with expanding profit margins. It manufactures domestically in five US facilities — a sixth is under construction in South Carolina. It benefits from Inflation Reduction Act tax credits through 2029. And it has just launched a new manufacturing process called CuRe — copper replacement — that increases panel lifetime energy yield by up to 8% and extends panel lifespan.


Everything checks out. Until you look at the guidance and the backlog.


Full year 2026 revenue is expected to come in flat to slightly down versus 2025. The order backlog, which peaked above 70 gigawatts in 2023, has now declined to under 48 gigawatts. First Solar is working through existing orders faster than it is winning new ones. A sizable cancellation from customer LightSource BP in 2024 and 2025 accelerated that decline. These are the hallmarks of a value trap — a stock that looks cheap because the future earning power is genuinely uncertain, not because the market has mispriced it.


The potential inflection point is a pending Section 232 investigation into whether crystalline silicon solar panel imports — primarily from China, where state-subsidized price dumping has been a recurring competitive tactic — constitute a national security risk. If the ruling lands in Q2 2026 and tariff protections follow, First Solar's order book could refill rapidly. If it does not, the backlog decline continues and the cheap valuation has every reason to stay cheap.


CSI walks through the full picture: the thin-film cadmium telluride technology edge, the CuRe manufacturing upgrade, the domestic supply chain advantage, the backlog reality, and a reverse DCF that shows the bar First Solar needs to clear is genuinely low — only 7% annual profit growth over five years with a 0% terminal rate gets you to today's price. The conclusion is honest: mildly interested, but the hallmarks of a value trap are present. Patience is the strategy.


What we cover:

— Why a solar company qualifies as a chip stock — and where First Solar fits in the supply chain

— First Solar Q1 2026: $1B+ revenue, record margins, $2.4B cash, minimal debt

— Thin-film cadmium telluride vs. crystalline silicon — the technology difference that matters

— The CURE manufacturing process: launching now in Ohio, targeted across all facilities

— Domestic US manufacturing as a competitive and geopolitical advantage

— The guidance problem: flat to down revenue in 2026

— The backlog decline: from 70GW in 2023 to under 48GW and still falling

— Section 232 tariff investigation — the binary catalyst expected Q2 2026

— Reverse DCF: 12.7x earnings, 7% growth, 0% terminal rate

— CSI verdict: mildly interested, but patient — the value trap signs are real


Disclosure: Nick and Kasey do not currently hold First Solar. This content is for general information only and is not individual investment advice. All investing involves risk.


chipstockinvestor.com

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(492)

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience (TWST) just had a massive run-up after Anthropic's protein design results put its DNA synthesis platform in the spotlight. Here's what's really driving the stock — and whether it's st...

17 Sep 14min

The Fastest-Growing Chip Stock Is Also the Most Hated

The Fastest-Growing Chip Stock Is Also the Most Hated

We compare Credo (CRDO) against Broadcom (AVGO), Marvell (MRVL), and Astera Labs (ALAB) on revenue growth, gross margin, operating margin, and free cash flow margin — four fabless companies selling in...

15 Sep 13min

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

We break down the takeaways from Oracle's (ORCL) Q1 fiscal 2027 earnings call — what to expect through 2026 and into 2027–2028 as hyperscaler CapEx stays high but is set to slow in growth by 2027, and...

14 Sep 12min

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia just proposed its largest acquisition ever — $12.9 billion for Hugging Face. But regulators in the US, EU, and China may have other plans.Nvidia has announced plans to acquire Hugging Face, the...

10 Sep 15min

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage just rebranded to Everpure — and in the same stretch, free cash flow went negative 20% in a single quarter. Here's what's really going on.Pure Storage has officially rebranded as Everpure...

10 Sep 19min

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept BioRobotics is down roughly 80% from its 2025 highs but the technology behind its Aquablation system genuinely works. So why won't we put PRCT in our portfolio?Procept (PRCT) has one of the mo...

10 Sep 28min

Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Oscar Health looks like a screaming buy — growing revenue, growing members, positive free cash flow. So why does the market keep discounting it? We ran the numbers.Oscar Health (OSCR) just posted stro...

10 Sep 11min

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Networks (PANW) has been flying high into the end of FY2026. After a decade-long 1,400% run — capped by a broader cybersecurity rally following the Anthropic "Mythos moment" in early 2026 — ...

2 Sep 14min

Populært innen Business og økonomi

stopp-verden
dine-penger-pengeradet
rss-penger-polser-og-politikk
e24-podden
rss-borsmorgen-okonominyhetene
rss-pa-konto
rss-skravla-gar
pengepodden-2
finansredaksjonen
tid-er-penger-en-podcast-med-peter-warren
lederpodden
stormkast-med-valebrokk-stordalen
livet-pa-veien-med-jan-erik-larssen
utbytte
rss-orjasater
pengesnakk
morgenkaffen-med-finansavisen
liberal-halvtime
lydartikler-fra-aftenposten
rss-markedspuls-2